BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 10, 2026
Breaking News: Best of BioWorld Science: Q1Breaking News: Regeneration in mammals is controlled by environmental conditionsBreaking News: Best of BioWorld Science: Q1
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Colorized scanning electron micrograph of MRSA.
Infection

Novel antibiotic based on dimethylcysteamine pleuromutilin

Oct. 16, 2025
No Comments
As part of global efforts to develop next-generation antibiotics to overcome the growing problem of bacterial resistance to existing drugs, researchers at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences prepared various derivatives of the dimethylcysteamine form of pleuromutilin, a naturally occurring diterpenoid.
Read More
Art concept for inflammation in the intestines
Gastrointestinal

Orchard’s OTL-104 is safe and efficacious in Crohn’s disease model

Oct. 16, 2025
No Comments

NOD2 deficiency is involved in the pathogenesis of Crohn’s disease (CD) due to failure of gut innate immunity and loss of intestinal tissue homeostasis. Orchard Therapeutics Ltd. has presented preclinical data on OTL-104, human hematopoietic stem cell (HSC) gene therapy for the treatment of NOD2-deficient CD.


Read More
Diagram of brain showing names of tumors and their location
Immuno-oncology

GPC2-targeted CAR T-cells show activity against medulloblastoma

Oct. 16, 2025
No Comments
Medulloblastoma (MB), the most common malignant pediatric brain tumor, represents about 20% of childhood central nervous system cancers.
Read More
Neurology/psychiatric

Potential next-generation multi-target drugs against Alzheimer’s disease

Oct. 16, 2025
No Comments
Researchers at Indian Institute of Technology (BHU) Varanasi and collaborators have designed inhibitors of cholinesterase based on benzothiazole-phenylpiperizine as a potential treatment for Alzheimer’s disease.
Read More
Photomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia
Cancer

Amphista nominates AMX-883 as development candidate

Oct. 16, 2025
No Comments
Amphista Therapeutics Ltd. has nominated AMX-883, a selective and orally bioavailable degrader of BRD9, as its first clinical development candidate. AMX-883 is being advanced for the treatment of acute myeloid leukemia (AML), with an IND application planned for early next year.
Read More
Illustration of DNA, magnifying glass
Genetic/congenital

Study identifies three new genes linked to cleft lip, palate risk

Oct. 16, 2025
No Comments
A recent study published in PLOS Genetics has identified several novel genetic variants associated with the risk of orofacial clefts, a common and complex congenital disability. Orofacial clefts are caused by a combination of genetic and environmental factors and can occur in isolation or simultaneously with other birth defects.
Read More
Immuno-oncology

Tagworks’ radioimmunoconjugate TGW-211 cleared for clinical trial

Oct. 16, 2025
No Comments
Tagworks Pharmaceuticals BV has announced approval by the Dutch regulatory authorities for a clinical trial application.
Read More
Two cells under neutral pH (left) compared to an acidic environment (right)
Cancer

Tumor cells reshape their energy metabolism under acidosis

Oct. 16, 2025
By Xavier Bofill Bruna
No Comments
Tumors suffer metabolic stress, such as oxygen and nutrient deficiency; as a result, altered metabolism is a common feature of tumors. Cancer cells enhance the production of energy and the synthesis of macromolecules to grow at pathologically increased rates. It is crucial to identify genes that modulate cellular fitness under these stressful scenarios.
Read More
Cancer

Littdd Medicines discovers new mTORC1 and mTORC2 inhibitors

Oct. 15, 2025
Littdd Medicines Ltd. has described mTOR complex 1 (mTORC1) and/or mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, transplant rejection, autoimmune and metabolic diseases, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease, among others.
Read More
Neurology/psychiatric

New LRRK2 inhibitors disclosed in Jingxin patent

Oct. 15, 2025
Researchers at Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have divulged compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.
Read More
Previous 1 2 … 163 164 165 166 167 168 169 170 171 … 18038 18039 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Connecting puzzle pieces

    Korsana boosts Alzheimer’s work with reverse merger, $380M financing

    BioWorld Science
    Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing